Lys189
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Ubiquitylation Site Page: > Lys189  -  CstF-64T (human)

Site Information
MDPEIALkILHRKIH   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 15386915

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 )
Disease tissue studied:
leukemia ( 7 ) , chronic myelogenous leukemia ( 7 )
Relevant cell line - cell type - tissue:
HEK293T (epithelial) ( 5 ) , HeLa (cervical) ( 8 ) , HEp-2 (squamous) ( 1 ) , Jurkat (T lymphocyte) ( 1 , 2 ) , K562 (erythroid) ( 7 ) , MV4-11 (macrophage) ( 5 ) , NCCIT (epithelial) ( 6 ) , U2OS (bone cell) ( 3 )

Upstream Regulation
Treatments:
MG132 ( 5 )

References 

1

Akimov V, et al. (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 25, 631-640
29967540   Curated Info

2

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

3

Povlsen LK, et al. (2012) Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass. Nat Cell Biol 14, 1089-98
23000965   Curated Info

4

Kim W, et al. (2011) Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 44, 325-40
21906983   Curated Info

5

Wagner SA, et al. (2011) A Proteome-wide, Quantitative Survey of In Vivo Ubiquitylation Sites Reveals Widespread Regulatory Roles. Mol Cell Proteomics 10, M111.013284
21890473   Curated Info

6

Zhou J (2010) CST Curation Set: 9131; Year: 2010; Biosample/Treatment: cell line, NCCIT/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

7

Moritz A (2010) CST Curation Set: 9063; Year: 2010; Biosample/Treatment: cell line, K-562/Peroxide; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

8

Moritz A (2010) CST Curation Set: 9062; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.